

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-17 (cancelled).

¹
Claim ~~18~~ (previously amended): An immunoassay method comprising the steps of:

- (a) reacting a monoclonal antibody specifically recognizing phosphatidylinositol-3,4,5-triphosphate, or a variable region thereof, with phosphatidylinositol-3,4,5-triphosphate present in a sample; and,
- (b) detecting the binding based on an immunological reaction between said antibody, or said variable region thereof, and said phosphatidylinositol-3,4,5-triphosphate; wherein, said monoclonal antibody binds to an antigenic determinant that contains an inositol group and a glycerol backbone in said phosphatidylinositol-3,4,5-triphosphate.

²
Claim ~~19~~ (previously amended): The immunoassay method of claim ~~18~~¹, wherein said monoclonal antibody does not cross-react with phosphatidylinositol-4,5-biphosphate.

³
Claim ~~20~~ (previously amended): An immunoassay method which comprises the steps of:

- (a) reacting a monoclonal antibody specifically recognizing phosphatidylinositol-3,4,5-triphosphate, or a variable region thereof, with phosphatidylinositol-3,4,5-triphosphate present in a sample; and,
- (b) detecting the binding based on an immunological reaction between said antibody, or said variable region thereof, and the ^{phosphatidylinositol-3,4,5-}triphosphate; wherein, said monoclonal antibody is an immunoglobulin, or ^avariable region thereof, which recognizes the phosphatidylinositol-3,4,5-triphosphate; wherein, said immunoglobulin, or said variable region thereof, comprises an immunoglobulin heavy chain comprising:

- (i) CDR1 comprising the amino acid sequence of SEQ ID NO: 5;
- (ii) CDR2 comprising the amino acid sequence of SEQ ID NO: 6; and,

(iii) CDR3 comprising the amino acid sequence of SEQ ID NO: 7.

⁴
Claim ~~21~~ (previously amended): The immunoassay method according to claim ³~~20~~, wherein said immunoglobulin comprises an immunoglobulin light chain comprising:

- (i) CDR1 comprising the amino acid sequence of SEQ ID NO: 8;
- (ii) CDR2 comprising the amino acid sequence of SEQ ID NO: 9; and,
- (iii) CDR3 comprising the amino acid sequence of SEQ ID NO: 10.

Claims 22-27 (cancelled).

Claim 28 (new): ~~A competitive immunoassay method that comprises the steps of:~~

- ~~(a) reacting a monoclonal antibody specifically recognizing phosphatidylinositol - 3,4,5-triphosphate, or a variable region thereof, with phosphatidylinositol -3,4,5-triphosphate present in a sample, in the presence of an immobilized antigenic determinant recognized by said antibody, to cause a competitive reaction between said immobilized antigenic determinant and phosphatidylinositol -3,4,5-triphosphate present in the sample with said monoclonal antibody, or said variable region thereof, and~~
- ~~(b) detecting the binding based on an immunological reaction between said monoclonal antibody, or said variable region thereof, and said immobilized antigenic determinant, wherein said monoclonal antibody binds to an antigenic determinant that contains an inositol group and a glycerol backbone in said phosphatidylinositol-3,4,5-triphosphate.~~